Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits
Megan Stringer, Charles R. Goodlett, Randall J. Roper
Molecular Genetics & Genomic Medicine (2017) Vol. 5, Iss. 5, pp. 451-465
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Emerging connections between cerebellar development, behaviour and complex brain disorders
A. G. Sathyanesan, Joy Zhou, Joseph Scafidi, et al.
Nature reviews. Neuroscience (2019) Vol. 20, Iss. 5, pp. 298-313
Open Access | Times Cited: 263
Human Models Are Needed for Studying Human Neurodevelopmental Disorders
Xinyu Zhao, Anita Bhattacharyya
The American Journal of Human Genetics (2018) Vol. 103, Iss. 6, pp. 829-857
Open Access | Times Cited: 139
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics
Dnyandev B. Jarhad, Karishma K. Mashelkar, Hong‐Rae Kim, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 22, pp. 9791-9810
Closed Access | Times Cited: 101
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
Mattias F. Lindberg, Laurent Meijer
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 6047-6047
Open Access | Times Cited: 81
Accelerated bio‐cognitive aging in Down syndrome: State of the art and possible deceleration strategies
Claudio Franceschi, Paolo Garagnani, Noémie Gensous, et al.
Aging Cell (2019) Vol. 18, Iss. 3
Open Access | Times Cited: 77
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B
Lee Walmsley, James B. Murray, P. Dokurno, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8971-8991
Closed Access | Times Cited: 33
Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases
Yuping Yang, Xiaoxiao Fan, Yongjian Liu, et al.
Biochemical Pharmacology (2023) Vol. 212, pp. 115521-115521
Closed Access | Times Cited: 14
Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [125I]Radioiodinated DYRK1A Inhibitor
Cayz G. Paclibar, Danielle Schafer, Agnes P. Biju, et al.
Molecules (2025) Vol. 30, Iss. 5, pp. 990-990
Open Access
Skeletal dynamics of Down syndrome: A developing perspective
Jonathan LaCombe, Randall J. Roper
Bone (2019) Vol. 133, pp. 115215-115215
Open Access | Times Cited: 37
Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice
Charles R. Goodlett, Megan Stringer, Jonathan LaCombe, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 33
Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome
John M. Starbuck, Sergi Llambrich, Rubèn Gonzàlez, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 29
Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study)
Cécile Cieuta‐Walti, Aida Cuenca‐Royo, Klaus Langohr, et al.
Genetics in Medicine (2022) Vol. 24, Iss. 10, pp. 2004-2013
Open Access | Times Cited: 21
Impact of Cre/LoxP-Mediated Chromosome Engineering Technology on Down Syndrome Research
Zhuo Xing, A. R. Douglas, Annie Pao, et al.
(2025), pp. 45-69
Closed Access
Overexpression screen of chromosome 21 genes reveals modulators of Sonic hedgehog signaling relevant to Down syndrome
Anna J. Moyer, Fabian‐Xosé Fernandez, Yicong Li, et al.
Disease Models & Mechanisms (2023) Vol. 16, Iss. 4
Open Access | Times Cited: 9
Dyrk1a is required for craniofacial development in Xenopus laevis.
H. Katherine Johnson, Stacey Wahl, Fatmata Sesay, et al.
Developmental Biology (2024) Vol. 511, pp. 63-75
Open Access | Times Cited: 3
Current Analysis of Skeletal Phenotypes in Down Syndrome
Jared Thomas, Randall J. Roper
Current Osteoporosis Reports (2021) Vol. 19, Iss. 3, pp. 338-346
Open Access | Times Cited: 19
Structure–Activity Relationship in the Leucettine Family of Kinase Inhibitors
Tania Tahtouh, Émilie Durieu, Benoît Villiers, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 1396-1417
Closed Access | Times Cited: 19
Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes
Miri Choi, Ae‐Kyeong Kim, Youngwook Ham, et al.
Phytomedicine (2021) Vol. 92, pp. 153695-153695
Open Access | Times Cited: 18
Sex specific emergence of trisomic Dyrk1a-related skeletal phenotypes in the development of a Down syndrome mouse model
Jonathan LaCombe, Kourtney Sloan, Jared Thomas, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model
Jonathan LaCombe, Kourtney Sloan, Jared Thomas, et al.
Disease Models & Mechanisms (2024) Vol. 17, Iss. 9
Open Access | Times Cited: 2
Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer’s Disease and Down Syndrome
Laurent Meijer, Emilie Chrétien, Denis Ravel
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S95-S113
Closed Access | Times Cited: 2
Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes
Laura E. Hawley, Faith Prochaska, Megan Stringer, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 217, pp. 173404-173404
Open Access | Times Cited: 10
Insights from the protein interaction Universe of the multifunctional “Goldilocks” kinase DYRK1A
Varsha Ananthapadmanabhan, Kathryn H. Shows, A J Dickinson, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 5
Loss of the DYRK1A Protein Kinase Results in the Reduction in Ribosomal Protein Gene Expression, Ribosome Mass and Reduced Translation
Chiara Di Vona, Laura Barba, Roberto Ferrari, et al.
Biomolecules (2023) Vol. 14, Iss. 1, pp. 31-31
Open Access | Times Cited: 5
Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome
Carmen Martínez Cué, Mara Dierssen
Progress in brain research (2019), pp. 269-302
Closed Access | Times Cited: 14
Page 1 - Next Page

Scroll to top